Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cc Biotech Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The current prosecution is handled by a distinct examiner and a distinct art unit. This concentration suggests a targeted approach to intellectual property within this specific technical field. By focusing on a single art unit, the company can develop a specialized prosecution strategy that accounts for the specific examination standards of that division.
The busiest examiner, ARMATO JR, DENNIS IGNATIUS, is responsible for 1 busiest examiner pending office action. This figure accounts for the entirety of the company's pending office actions. With only 1 distinct examiner and 1 distinct art unit involved, the company's immediate prosecution strategy is focused on resolving the issues raised by this single examiner. Practitioners should prioritize the specific feedback from ARMATO JR, DENNIS IGNATIUS, as the resolution of this 1 pending office action is the only current path to securing patent rights for the company in this technology area.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARMATO JR, DENNIS IGNATIUS | 1 | 42.9% | +80.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037632 | POLYPEPTIDES FOR TREATMENT OF BACTERIAL INFECTIONS | ARMATO JR, DENNIS IGNATIUS | 73d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037632 | POLYPEPTIDES FOR TREATMENT OF BACTERIAL INFECTIONS | ARMATO JR, DENNIS IGNATIUS | 73d overdue |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18037632 | POLYPEPTIDES FOR TREATMENT OF BACTERIAL INFECTIONS | ARMATO JR, DENNIS IGNATIUS | 1651 | §103§112Other | Final Rejection | 73d overdue | Pending | May 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial